Pharma, Biotech and Generics Industry News | The Pharmaletter
9 December 2024 The pharmacovigilance (PV) teams within the pharmaceutical industry currently report allocating 40 to 85% of budgets towards case processing. With case processing volumes growing at a rate of 10 to 15% annually, life sciences organizations are aiming to reduce costs and automate time-consuming processes while maintaining or improving quality.
Novo Nordisk settles patent lawsuit over Ozempic
Oct 8, 2024 · Novo Nordisk (NOV: N) has reached a settlement with Mylan Pharmaceuticals, part of Viatris (Nasdaq: VTRS), concluding a US patent lawsuit over diabetes drug Ozempic (semaglutide). The lawsuit aimed to protect Ozempic’s market exclusivity until 2032. Mylan and Natco Pharma are developing a generic version, with exclusivity for six months after approval.
Trump vs Harris—who's on Big Pharma's side? | Pharmaceutical
Sep 22, 2024 · In the 2024 US presidential election, health policy will remain a key issue for pharma. Both Donald Trump and Kamala Harris have criticized high drug prices, raising uncertainty for the industry. While Trump targeted generics, biosimilars, and international price comparisons during his term, Harris has been associated with pricing transparency and the Inflation Reduction Act (IRA), which ...
Oblenio Bio | The Pharmaletter
Nov 7, 2024 · The company was launched by Aditum Bio in November 2024. Oblenio Bio was formed in conjunction with an exclusive option and license agreement with launched by Aditum Bio to develop LBL-051, a novel tri-specific T-cell engager developed using …
Vertex Pharmaceuticals News | The Pharmaletter
Dec 18, 2024 · US biopharma Vertex Pharmaceuticals today announced results from its Phase II study of suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor in people with painful lumbosacral radiculopathy (LSR), also known as sciatica.
Kura and Kyowa Kirin sign ziftomenib deal | The Pharmaletter
Nov 21, 2024 · This article is accessible to registered users, to continue reading please register for free.. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week.
The week in pharma: action, reaction and insight – week to …
Nov 24, 2024 · Research news last week included US biotech Fate releasing early data for its FT819 in the treatment of systemic lupus erythematosus (SLE), which sent the firm’s shares leaping as much as 70%. Also, Netherlands-based NewAmsterdam Pharma announced positive data on its obicetrapib and ezetimibe combination in cardiovascular disease. On the regulatory front, Dutch firm argenX and China’s Zai ...
BeOne Medicines | The Pharmaletter
Formerly known as BeiGene, the company changed its name in November 2024 as part of a broader strategic growth plan. To support its expansive clinical portfolio and global growth, the company opened its $800 million flagship clinical R&D and manufacturing facility at the Princeton West Innovation Campus in Hopewell, N.J. in July 2024.
Collaboration targets automation in CGT manufacturing
Oct 16, 2024 · Cellular Origins and Fresenius Kabi have partnered to integrate Fresenius Kabi's cell therapy processing tech with Cellular Origins' robotic manufacturing platform, Constellation. This collaboration aims to streamline scalable CGT production through automation, improving efficiency and access to life-saving therapies
Paragon Therapeutics appoints first chief executive
Nov 22, 2024 · US biotech Paragon Therapeutics yesterday revealed that biotech industry veteran Susanna High has been appointed as chief executive (CEO). In this newly-created role, Ms High will lead the team’s continued efforts to propel the development of a pipeline of transformative therapies and accelerate their potential impact.